ArticleOpen life sciences2026
UC-MSCs exhibit superior antifibrotic and anti-inflammatory effects compared to BM-MSCs in a bleomycin-induced idiopathic pulmonary fibrosis model.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Efficacy of Co-administered WJ-MSCs and Exosomes in a Rat Pulmonary Fibrosis Model.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by excessive tissue buildup and reduced lung function, with few effective treatment options available. This study investigates the effectiveness of umbilical cord-derived mesenchymal stem cells (UC-MSCs) compared to bone marrow-derived mesenchymal stem cells (BM-MSCs) in a mouse model of bleomycin-induced IPF. Male BALB/c mice were divided into four groups: control, bleomycin-induced pulmonary fibrosis, UC-MSC treatment, and BM-MSC treatment. IPF was induced by administering bleomycin, followed by UC-MSC or BM-MSC treatment on day 14. Lung tissues and bronchoalveolar lavage fluid were collected on day 42 for analysis. The results demonstrated that UC-MSCs were more effective than BM-MSCs in reducing mortality, alleviating body weight loss, and reversing lung damage. UC-MSC treatment significantly decreased profibrotic markers like TGF-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.